Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, Earum Pharmaceuticals has informed that Payal Patel has resigned from the position of the Chief Financial Officer of the Company with effect from 9th August, 2023. Further, the Company has received confirmation from Payal Patel that there are no other material reasons for her resignation other than those which are provided in the resignation letter. The relevant details in terms of SEBI (LODR) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
